Natera, Inc. (NASDAQ:NTRA) Director Sells $590,760.00 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 4,000 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total transaction of $590,760.00. Following the completion of the transaction, the director now directly owns 9,704 shares in the company, valued at $1,433,183.76. The trade was a 29.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Natera Trading Up 4.0 %

NTRA opened at $148.22 on Monday. The company’s 50 day moving average is $163.70 and its 200-day moving average is $148.83. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The company has a market cap of $20.04 billion, a P/E ratio of -84.22 and a beta of 1.80.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Hedge funds have recently added to or reduced their stakes in the business. LRI Investments LLC bought a new position in Natera during the 4th quarter worth approximately $29,000. Blue Trust Inc. raised its holdings in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc raised its holdings in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares during the last quarter. Finally, Principal Securities Inc. raised its holdings in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on NTRA. Royal Bank of Canada began coverage on shares of Natera in a research report on Thursday. They issued an “outperform” rating and a $251.00 price objective on the stock. Guggenheim raised their price target on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Piper Sandler raised their price target on shares of Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. BTIG Research reaffirmed a “buy” rating on shares of Natera in a research report on Friday, February 28th. Finally, The Goldman Sachs Group raised their price target on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.